Todd Franklin Watanabe, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 50,030 shares at $13.28 ($654K) on 2025-03-04, disclosed to the SEC on 2025-03-04.
Scheduled sale ($654k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.03 | 20,880 | $272K | 41.6% |
| 2 | $13.03 | 20,880 | $272K | 41.6% |
| 3 | $13.28 | 4,135 | $55K | 8.4% |
| 4 | $13.28 | 4,135 | $55K | 8.4% |
| Total | $13.07 avg | 50,030 | $654K | 100% |
| Filing → |
| ARQT | SELL | 2025-03-20 | $21K | — | Filing → |
| ARQT | SELL | 2025-02-04 | $490K | — | Filing → |
| ARQT | SELL | 2024-12-23 | $228K | — | Filing → |